125 related articles for article (PubMed ID: 9530768)
1. [Total illness costs of schizophrenia and monetary evaluation of prevention of recurrence exemplified by a standard depot neuroleptic (flupenthixol decanoate)].
Osterheider M; Franken-Hiep K; Horn R
Psychiatr Prax; 1998 Jan; 25(1):38-43. PubMed ID: 9530768
[TBL] [Abstract][Full Text] [Related]
2. [Effect of combined pharmaco- and psychotherapy in schizophrenia ambulatory care on rehospitalization incidents and treatment costs].
Müller P; Schöneich D
Psychiatr Prax; 1992 Jul; 19(4):91-5. PubMed ID: 1354881
[TBL] [Abstract][Full Text] [Related]
3. [The impact of antipsychotic medication on the incidence and the costs of inpatient treatment in people with schizophrenia: results from a prospective observational study].
Kilian R; Angermeyer MC
Psychiatr Prax; 2004 Apr; 31(3):138-46. PubMed ID: 15042477
[TBL] [Abstract][Full Text] [Related]
4. [The risk of rehospitalisation during therapy with atypical and typical neuroleptics--a contribution to differential indication].
Müller P; Nerenz H; Schaefer E
Psychiatr Prax; 2002 Oct; 29(7):388-91. PubMed ID: 12378421
[TBL] [Abstract][Full Text] [Related]
5. [Intervals between hospitalisations in schizophrenia patients under antipsychotics in depot-form versus oral second generation antipsychotics].
Gutwinski S; Müller P; Koller M
Psychiatr Prax; 2007 Sep; 34(6):289-91. PubMed ID: 17806015
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia.
Obradovic M; Mrhar A; Kos M
Int J Clin Pract; 2007 Dec; 61(12):1979-88. PubMed ID: 17997804
[TBL] [Abstract][Full Text] [Related]
7. [Costs of early retirement--the case of schizophrenia].
Clouth J
Psychiatr Prax; 2004 Nov; 31 Suppl 2():S238-45. PubMed ID: 15586317
[TBL] [Abstract][Full Text] [Related]
8. [Non-compliance and lack of indications for depot treatment as reasons for exclusion from adequate prevention of recurrence].
Jakobitsch A; Haug HJ; Greger J; Osterheide M; Pach J; Sprenger R; Tegeler J; Budde G
Psychiatr Prax; 1996 Sep; 23(5):236-9. PubMed ID: 8992517
[TBL] [Abstract][Full Text] [Related]
9. Flupenthixol decanoate and fluphenazine decanoate in chronic schizophrenia.
Kong DS; Yeo SH
Singapore Med J; 1985 Dec; 26(7):551-5. PubMed ID: 3834613
[No Abstract] [Full Text] [Related]
10. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
Marcus SC; Olfson M
Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
[TBL] [Abstract][Full Text] [Related]
11. Radioreceptor assay in checking serum concentration in long-term treatment with cis(z)-flupenthixol decanoate.
Lipska B; Welbel L; Nurowska K; Szukalski B
Act Nerv Super (Praha); 1987 Dec; 29(4):270-3. PubMed ID: 3439426
[TBL] [Abstract][Full Text] [Related]
12. Clinical trial of flupenthixol decanoate in chronic withdrawn schizophrenic patients.
Vichaiya V
J Med Assoc Thai; 1980 Apr; 63(4):205-9. PubMed ID: 6991627
[No Abstract] [Full Text] [Related]
13. Successful treatment with flupenthixol decanoate of a patient with both schizophrenia and alcoholism.
Soyka M; Sand P
Pharmacopsychiatry; 1995 Mar; 28(2):64-5. PubMed ID: 7624388
[TBL] [Abstract][Full Text] [Related]
14. [Quality of life and therapeutic result in outpatients with schizophrenia under flupenthixol treatment].
Kühn KU; Quednow BB; Landen H; Riedel M; Thiel M
Fortschr Neurol Psychiatr; 2004 Jul; 72(7):397-403. PubMed ID: 15252753
[TBL] [Abstract][Full Text] [Related]
15. [The analysis of the cost structures of the treatment of schizophrenia by means of standardized assessment instruments].
Kilian R; Roick C; Matschinger H; Bernert S; Mory C; Angermeyer MC
Psychiatr Prax; 2001 Oct; 28 Suppl 2():S102-8. PubMed ID: 11605132
[TBL] [Abstract][Full Text] [Related]
16. Cost of relapse in schizophrenia.
Weiden PJ; Olfson M
Schizophr Bull; 1995; 21(3):419-29. PubMed ID: 7481573
[TBL] [Abstract][Full Text] [Related]
17. [Longitudinal analysis of factors influencing direct costs of schizophrenia treatment].
Kilian R; Matschinger H; Angermeyer MC
Gesundheitswesen; 2003 Mar; 65(3):173-80. PubMed ID: 12698387
[TBL] [Abstract][Full Text] [Related]
18. Fluphenazine and flupenthixol decanoate in psychiatric outpatients practice.
Coufal J; Novotný M
Act Nerv Super (Praha); 1981 Dec; 23(4):269-71. PubMed ID: 6121439
[No Abstract] [Full Text] [Related]
19. Continuation ECT in treatment-resistant schizophrenia: a controlled study.
Chanpattana W; Chakrabhand ML; Sackeim HA; Kitaroonchai W; Kongsakon R; Techakasem P; Buppanharun W; Tuntirungsee Y; Kirdcharoen N
J ECT; 1999 Sep; 15(3):178-92. PubMed ID: 10492856
[TBL] [Abstract][Full Text] [Related]
20. [Methodolocical issues of naturalistic observational studies on the economic evaluation of neuroleptic treatment for schizophrenic disease].
Kilian R; Angermeyer MC; Becker T
Gesundheitswesen; 2004 Mar; 66(3):180-5. PubMed ID: 15088222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
